{"prompt": "['Product: MK-3475', '93', 'Protocol/Amendment No.: 604-09', 'eCRF. Survival assessments and their respective entries into the database may be required', 'more frequently around the time of the projected analyses (eg, DMC reviews, interim', 'analyses). For subjects who die during the follow-up period, the date and cause of death', 'should be recorded in the appropriate eCRF.', '7.2 Assessing and Recording Adverse Events', 'An adverse event is defined as any untoward medical occurrence in a patient or clinical', 'investigation subject administered a pharmaceutical product and which does not necessarily', 'have to have a causal relationship with this treatment. An adverse event can therefore be any', 'unfavourable and unintended sign (including an abnormal laboratory finding, for example),', 'symptom, or disease temporally associated with the use of a medicinal product or protocol-', 'specified procedure, whether or not considered related to the medicinal product or protocol-', 'specified procedure. Any worsening (i.e., any clinically significant adverse change in', 'frequency and/or intensity) of a preexisting condition that is temporally associated with the', \"use of the Sponsor's product, is also an adverse event.\", 'Changes resulting from normal growth and development that do not vary significantly in', 'frequency or severity from expected levels are not to be considered adverse events.', 'Examples of this may include, but are not limited to, teething, typical crying in infants and', 'children and onset of menses or menopause occurring at a physiologically appropriate time.', \"Sponsor's product includes any pharmaceutical product, biological product, device,\", 'diagnostic agent or protocol-specified procedure, whether investigational (including placebo', 'or active comparator medication) or marketed, manufactured by, licensed by, provided by or', 'distributed by the Sponsor for human use.', 'Adverse events may occur during clinical trials, or as prescribed in clinical practice, from', 'overdose (whether accidental or intentional), from abuse and from withdrawal.', 'Progression of the cancer under study is not considered an adverse event.', 'All adverse events that occur after the consent form is signed but before treatment', 'allocation/randomization must be reported by the investigator if they cause the subject to be', 'excluded from the trial, or are the result of a protocol-specified intervention, including but', 'not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a', 'procedure. From the time of treatment allocation/randomization through 30 days following', 'cessation of treatment, all adverse events must be reported by the investigator. Such events', 'will be recorded at each examination on the Adverse Event case report forms/worksheets.', 'The reporting timeframe for adverse events meeting any serious criteria is described in', 'Section 7.2.3.1. The investigator will make every attempt to follow all subjects with non-', 'serious adverse events for outcome.', 'Electronic reporting procedures can be found in the Electronic Data Capture (EDC) data', 'entry guidelines. Paper reporting procedures can be found in the Investigator Trial File', 'Binder (or equivalent).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '94', 'Protocol/Amendment No.: 604-09', '7.2.1 Definition of an Overdose for This Protocol and Reporting of Overdose to the', 'Sponsor', 'For purposes of this trial, an overdose will be defined as any dose exceeding the prescribed', 'dose for pembrolizumab by >1000 mg (5 times the dose). For subjects treated with', 'pembrolizumab an overdose will be defined as any dose exceeding 5X the', 'protocol-prescribed dose. No specific information is available on the treatment of overdose', 'of pembrolizumab. In the event of overdose, pembrolizumab should be discontinued and the', 'subject should be observed closely for signs of toxicity. Appropriate supportive treatment', 'should be provided if clinically indicated.', 'If an adverse event(s) is associated with (\"results from\") the overdose of Sponsor\\'s product,', 'the adverse event(s) is reported as a serious adverse event, even if no other seriousness', 'criteria are met.', \"If a dose of Sponsor's product meeting the protocol definition of overdose is taken without\", 'any associated clinical symptoms or abnormal laboratory results, the overdose is reported as', 'a non-serious Event of Clinical Interest (ECI), using the terminology \"accidental or', 'intentional overdose without adverse effect.\"', 'All reports of overdose with and without an adverse event must be reported by the', 'investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic', 'reporting procedures can be found in the EDC data entry guidelines. Paper reporting', 'procedures can be found in the Investigator Trial File Binder (or equivalent).', '7.2.2 Reporting of Pregnancy and Lactation to the Sponsor', 'Although pregnancy and lactation are not considered AEs, it is the responsibility of', 'investigators or their designees to report any pregnancy or lactation in a subject', '(spontaneously reported to them) that occurs during the trial.', 'Pregnancies and lactations that occur after the consent form is signed but before treatment', 'allocation/randomization must be reported by the investigator if they cause the subject to be', 'excluded from the trial or are the result of a protocol-specified intervention, including but not', 'limited to washout or discontinuation of usual therapy, diet, placebo treatment or a', 'procedure. Pregnancies and lactations that occur from the time of treatment', \"allocation/randomization through 120 days following cessation of Sponsor's product, or\", '180 days after last dose of chemotherapeutic agents, or 30 days following cessation of trial', 'treatment if the subject initiates new anticancer therapy, whichever is earlier, must be', 'reported by the investigator. All reported pregnancies must be followed to the', 'completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion,', 'missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death,', 'miscarriage and stillbirth must be reported as serious events (Important Medical Events). If', 'the pregnancy continues to term, the outcome (health of infant) must also be reported.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}